<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260124068649N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-01-30</date_registration>
      <primary_sponsor>Rasht University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of Using Osseodensification Drills on the Stability of Dental Implants</public_title>
      <acronym></acronym>
      <scientific_title>The Effect of Using Osseodensification Drills on the Stability of Dental Implants in the Maxilla: A Randomized Split‑Mouth Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-02-19</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>12</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/88826</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this split‑mouth randomized clinical trial, treatment type and jaw side are allocated using permuted block randomization with a block size of 4. The random sequence is generated using SAS software (version 9), with A/B indicating treatment type and C/D indicating jaw side. Only the data analyst is aware of the allocation codes.
Allocation concealment is ensured using sealed, opaque, numbered envelopes prepared by an independent researcher. After patient enrollment, one envelope is opened to determine the assigned treatment and jaw side. Implant surgery is performed by one researcher, while data collection and outcome assessment are carried out by another researcher blinded to allocation, Blinding description: The intervention will be performed bilaterally in the maxilla for each patient, and both drilling techniques (osseodensification and conventional drilling) will be used in every participant. Participants will be blinded to the allocation of the drilling technique to each side. 
The surgical procedures will be performed by one investigator, while outcome assessment and data collection will be carried out by a second investigator who is blinded to group allocation. Only the data analyst will have access to the treatment codes.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Maxillary Partial Edentulism requiring Dental Implants.</hc_freetext>
      <i_freetext>Intervention 1: Interventions group: In the intervention group, implant site preparation will be performed using the osseodensification technique. For this purpose, the Charisma osseodensification drill kit (manufacturer: Pakistan) will be used.In this technique, the drills are operated in a counter‑clockwise rotation with the aim of compacting and preserving the peri‑implant bone. Unlike conventional drilling, this method is a non‑excavation technique, in which bone is not removed from the osteotomy site.Osteotomy preparation will be carried out according to the manufacturer’s instructions. After completion of the osteotomy, Dio dental implants with dimensions of 8.3 × 10 mm (regular type) will be placed using an implant motor at a speed of 30 rpm and an insertion torque of 30 Ncm. Intervention 2: control group: In the control group, implant site preparation will be performed using the conventional subtractive drilling technique. A standard DIO drilling kit (manufactured in South Korea) will be used according to the manufacturer’s recommended protocol.In this method, the osteotomy is prepared through gradual removal of bone, with sequential use of drills of increasing diameters until the final osteotomy size is achieved.Following site preparation, implants with specifications identical to those used in the intervention group (Dio, 8.3 × 10 mm, regular type) will be placed at a speed of 30 rpm and an insertion torque of 30 Ncm.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is We are currently evaluating the feasibility and ethical‑legal implications of sharing de‑identified IPD. Key considerations include participant re‑consent, data anonymization techniques, institutional policies, and resource availability. A final decision will be made after consultation with our ethics committee and data‑protection officer.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ashkan Salari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rasht, Saravan road to Foman, Gilan Dental Clinic</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4194173774</zip>
        <telephone>+98 13 3348 6406</telephone>
        <email>Drashkan_salary@yahoo.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ashkan Salari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rasht, Saravan road to Foman, Gilan Dental Clinic</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4194173774</zip>
        <telephone>+98 13 3348 6406</telephone>
        <email>Drashkan_salary@yahoo.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age 18 years or older
Indication for placement of two implants in the premolar regions on both sides of the jaw, in edentulous areas at least 6 months after tooth extraction
Bone density: D3–D4</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Presence of acute or chronic infection or local pathology at the intended implant placement site
Patients with parafunctional habits
Limitations to implant placement, such as insufficient vertical bone height
Use of medications that interfere with bone healing, such as corticosteroids, hormone therapy, or bisphosphonates
History of uncontrolled systemic diseases or conditions that interfere with bone healing, including smoking, diabetes, immunosuppression, fibrous dysplasia, bleeding disorders, hyperparathyroidism, pregnancy, and a history of head and neck radiotherapy or chemotherapy within the past 5 years</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K08.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Partial loss of teeth</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Interventions group: In the intervention group, implant site preparation will be performed using the osseodensification technique. For this purpose, the Charisma osseodensification drill kit (manufacturer: Pakistan) will be used.In this technique, the drills are operated in a counter‑clockwise rotation with the aim of compacting and preserving the peri‑implant bone. Unlike conventional drilling, this method is a non‑excavation technique, in which bone is not removed from the osteotomy site.Osteotomy preparation will be carried out according to the manufacturer’s instructions. After completion of the osteotomy, Dio dental implants with dimensions of 8.3 × 10 mm (regular type) will be placed using an implant motor at a speed of 30 rpm and an insertion torque of 30 Ncm.</i_keyword>
      <i_keyword>control group: In the control group, implant site preparation will be performed using the conventional subtractive drilling technique. A standard DIO drilling kit (manufactured in South Korea) will be used according to the manufacturer’s recommended protocol.In this method, the osteotomy is prepared through gradual removal of bone, with sequential use of drills of increasing diameters until the final osteotomy size is achieved.Following site preparation, implants with specifications identical to those used in the intervention group (Dio, 8.3 × 10 mm, regular type) will be placed at a speed of 30 rpm and an insertion torque of 30 Ncm.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Implant Stability. Timepoint: Immediately, 2, 8, and 12 weeks after implant placement. Method of measurement: Implant stability will be measured using the AnyCheck device (Neo Biotech, South Korea) in direct contact with the healing abutment.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Marginal Bone Loss. Timepoint: Three months after implant placement. Method of measurement: Measurement of the distance between the first thread of the implant and the crestal bone on parallel periapical radiographs, recorded in tenths of a millimeter.</sec_outcome>
      <sec_outcome>Patient-reported Pain &amp; Discomfort. Timepoint: Immediately after the surgery and one week after implant placement. Method of measurement: The level of pain and discomfort experienced by patients will be measured using the Visual Analog Scale (VAS).</sec_outcome>
      <sec_outcome>Initial survival rate. Timepoint: Three months after implant placement. Method of measurement: Evaluating the survival rate of the implants in the follow-up session.</sec_outcome>
      <sec_outcome>Bone density. Timepoint: 12 weeks after implant placement. Method of measurement: The bone density of the area around the implant will be classified using CBCT and the Lekholm &amp; Zarb classification into five categories: D1, D2, D3, D4, and D5.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rasht University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-01-14</approval_date>
        <contact_name>Research Ethics Committees of Guilan university of medical sciences</contact_name>
        <contact_address>Fouman - Saravan Rd Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
